Download PDF
1 / Pages

Other users also viewed these articles

Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis Burak Okyar; Servet Yüce; ¿brahim Halil Bilen; Bekir Torun; ¿lyas Öztürk; Gözde Y¿ld¿r¿m Çetin;
Reumatol Clin. 2024;20:533-8
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;
Reumatol Clin. 2024;20:123-7
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48